Gáll Zsolt, Boros Bernadett, Kelemen Krisztina, Urkon Melinda, Zolcseak István, Márton Kincső, Kolcsar Melinda
Department of Pharmacology and Clinical Pharmacy, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, Târgu Mures, Romania.
Faculty of Pharmacy, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, Târgu Mures, Romania.
Front Pharmacol. 2024 Jul 29;15:1447757. doi: 10.3389/fphar.2024.1447757. eCollection 2024.
Alzheimer's disease (AD) and other forms of dementia have a devastating effect on the community and healthcare system, as neurodegenerative diseases are causing disability and dependency in older population. Pharmacological treatment options are limited to symptomatic alleviation of cholinergic deficit and accelerated clearance of β-amyloid aggregates, but accessible disease-modifying interventions are needed especially in the early phase of AD. Melatonin was previously demonstrated to improve cognitive function in clinical setting and experimental studies also.
In this study, the influence of melatonin supplementation was studied on behavioral parameters and morphological aspects of the hippocampus and amygdala of rats. Streptozotocin (STZ) was injected intracerebroventricularly to induce AD-like symptoms in male adult Wistar rats (n = 18) which were compared to age-matched, sham-operated animals (n = 16). Melatonin was administered once daily in a dose of 20 mg/kg body weight by oral route. Behavioral analysis included open-field, novel object recognition, and radial-arm maze tests. TNF-α and MMP-9 levels were determined from blood samples to assess the anti-inflammatory and neuroprotective effects of melatonin. Immunohistological staining of brain sections was performed using anti-NeuN, anti-IBA-1, and anti-GFAP primary antibodies to evaluate the cellular reorganization of hippocampus.
The results show that after 40 days of treatment, melatonin improved the cognitive performance of STZ-induced rats and reduced the activation of microglia in both CA1 and CA3 regions of the hippocampus. STZ-injected animals had higher levels of GFAP-labeled astrocytes in the CA1 region, but melatonin treatment reduced this to that of the control group. In conclusion, melatonin may be a potential therapeutic option for treating AD-like cognitive decline and neuroinflammation.
阿尔茨海默病(AD)和其他形式的痴呆症对社区和医疗保健系统具有毁灭性影响,因为神经退行性疾病正在导致老年人群出现残疾和依赖。药物治疗选择仅限于对症缓解胆碱能缺陷和加速β-淀粉样蛋白聚集体的清除,但需要可及的疾病修饰干预措施,尤其是在AD的早期阶段。褪黑素先前在临床环境和实验研究中均已证明可改善认知功能。
在本研究中,研究了补充褪黑素对大鼠海马体和杏仁核行为参数及形态学方面的影响。向成年雄性Wistar大鼠(n = 18)脑室内注射链脲佐菌素(STZ)以诱导类AD症状,并与年龄匹配的假手术动物(n = 16)进行比较。通过口服途径以20 mg/kg体重的剂量每日给药一次褪黑素。行为分析包括旷场试验、新物体识别试验和放射状臂迷宫试验。从血样中测定肿瘤坏死因子-α(TNF-α)和基质金属蛋白酶-9(MMP-9)水平,以评估褪黑素的抗炎和神经保护作用。使用抗神经元核抗原(NeuN)、抗离子钙结合衔接分子1(IBA-1)和抗胶质纤维酸性蛋白(GFAP)一抗对脑切片进行免疫组织化学染色,以评估海马体的细胞重组。
结果表明,治疗40天后,褪黑素改善了STZ诱导大鼠的认知表现,并减少了海马体CA1和CA3区域小胶质细胞的激活。注射STZ的动物在CA1区域GFAP标记的星形胶质细胞水平较高,但褪黑素治疗将其降低至对照组水平。总之,褪黑素可能是治疗类AD认知衰退和神经炎症的一种潜在治疗选择。